Christopher Nathan Martin - 11 Dec 2025 Form 4 Insider Report for Oruka Therapeutics, Inc. (ORKA)

Role
Director
Signature
/s/ Paul Quinlan, as attorney-in-fact for Christopher Martin
Issuer symbol
ORKA
Transactions as of
11 Dec 2025
Net transactions value
$0
Form type
4
Filing time
11 Dec 2025, 16:41:00 UTC
Previous filing
24 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Martin Christopher Nathan Director C/O ORUKA THERAPEUTICS, INC., 855 OAK GROVE AVE., SUITE 100, MENLO PARK /s/ Paul Quinlan, as attorney-in-fact for Christopher Martin 11 Dec 2025 0002097992

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORKA Stock Option (right to buy) Award $0 +35,000 $0.000000 35,000 11 Dec 2025 Common Stock 35,000 $30.21 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 1/36 of the underlying shares monthly from December 11, 2025.